Navigation Links
Global Autoimmune Disease Therapeutics Market to Reach $50 Billion by 2015, According to a New Report by Global Industry Analysts
Date:6/30/2009

GIA announces the release of a comprehensive global report on Autoimmune Disease Therapeutics market. With the global incidence and prevalence of autoimmune diseases increasing, the market for drugs used in the treatment of these diseases is expected to flourish in the near future. Key factors driving this growth include increasing use of biologics, as against conventional treatment options. Priced higher than conventional drugs, biologic drugs continue to drive revenues for manufacturers. Besides, factors such as unmet medical needs and an extensive pipeline of drugs that bode superior efficacy, keep growth prospects optimistic.

San Jose, CA (PRWEB) June 30, 2009 -- Global market for Autoimmune Disease Therapeutics is projected to reach US$49.8 billion in 2015. Biologics emerged as the leading therapeutic option in the treatment of autoimmune diseases, owing to their superior efficacy compared to conventional small molecule drugs. Fueling growth are factors such as introduction of new products, enhanced access to drugs, and enhanced penetration of existing drugs. Access to biologics in the world's largest drug market, the US, is due primarily to the inclusion of Humira and Enbrel into Medicare Part D reimbursement in early 2006. New products that are being launched in the market provide expanded therapeutic options for patients who fail to respond to existing therapies. The United States represents the largest market for biological autoimmune disease therapeutics, while Europe represents the fastest growing market worldwide. Rheumatoid Arthritis represents the largest segment in the global market, while Crohn's Disease represents the fastest growing segment for biologics in the global autoimmune disease therapeutics market.

Lack of awareness on the disease and associated symptoms curbed accurate diagnosis of autoimmune diseases in the past. Symptoms of most autoimmune diseases are similar to that of certain common conditions that lead to wrong diagnoses, and consequently raise healthcare costs. Rapid advancement in the area of disease diagnostics is increasingly enabling physicians in making accurate diagnosis of various autoimmune diseases, which is resulting in a rise in number of patients diagnosed, and subsequently higher number of patients receiving therapy. Leading biological drugs in the present day treatment of autoimmune diseases include TNF inhibitors, such as Enbrel, Humira and Remicade. New products in the market, such as Rituxan and Orencia made significant inroads by addressing therapeutic needs not addressed by existing drugs.

The global marketplace is characterized by participants such as Abbott Laboratories, Amgen Inc., Bayer Schering Pharma AG, Biogen Idec Inc., Bristol-Myers Squibb Company, Chugai Pharmaceutical Co., Ltd., Elan Corporation, plc, Eli Lilly And Company, F. Hoffmann-La Roche AG, Genentech, Inc., GlaxoSmithKline plc, Johnson & Johnson, Inc., Merck Serono SA, Novartis AG, sanofi-aventis SA, Schering-Plough Corporation, Shire Pharmaceuticals Group plc., Teva Pharmaceuticals Industries Limited, UCB Pharma.

"Autoimmune Disease Therapeutics: A Global Strategic Business Report" announced by Global Industry Analysts, Inc. provides a comprehensive review of market trends, drivers, product profile, players, competition, recent developments, mergers, acquisitions, and other strategic industry activities. Analysis is presented for major geographic markets such as the US, Japan, Europe and Rest of World. Global and regional analytics are provided for product segments such as Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Crohn's Disease and Other Autoimmune Diseases.

For more details about this comprehensive market research report, please visit - http://www.strategyr.com/Autoimmune_Disease_Therapeutics_Market_Report.asp

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs over 800 people worldwide and publishes more than 1100 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.
Telephone 408-528-9966
Fax 408-528-9977
Email press (at) StrategyR (dot) com
Web Site http://www.StrategyR.com/

###

Read the full story at http://www.prweb.com/releases/2009/06/prweb2528754.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Corbett Selected to Host the Only Midwest Global Awards Judging Competition
2. Tata Consultancy Services to Support Roches Global Capacity Building Initiative
3. Creative Technology Services Enhances its Global Competitiveness with Additional Regulatory Certifications
4. Briefing on a new Web resource to address global drinking water crisis
5. MDS Pharma Services Wins Award for Management of Global Malaria Trial
6. Neusoft Becomes First Global Growth Company Partner of World Economic Forum
7. Resonant Medical Appoints New Vice President of Global Sales
8. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
9. The era of global aging: GSAs annual meeting to present new research on hot topics in aging
10. MEDEX Global Group & Harvard Medical International Join Forces to Create the Most Comprehensive Health Information Resource for International Travelers
11. Ultrasonix Adds Global Medical Imaging Into Its North American Sales Force
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Global Autoimmune Disease Therapeutics Market to Reach $50 Billion by 2015, According to a New Report by Global Industry Analysts
(Date:8/16/2017)... and CARTERSVILLE, Georgia (PRWEB) , ... August 16, 2017 , ... ... the fastest growing companies in the U.S. for the second year in a row. ... growth over the past three years. , “To be on the list once is ...
(Date:8/16/2017)... Atlanta, GA (PRWEB) , ... August 16, 2017 , ... ... the new Inc. 5000. The company ranked #4429 on the newly released, 36th annual ... The list represents a unique look at the most successful companies within the American ...
(Date:8/16/2017)... ... 16, 2017 , ... In a recent survey, eighty-two percent of women reported ... fact, cellulite can't always be eliminated by diet and exercise alone, and now for ... physicians nationwide. Dr. Kenneth Rothaus has recently added Cellulaze™ to his practice ...
(Date:8/16/2017)... Long Island, NY (PRWEB) , ... August 16, 2017 , ... ... assist with IV starts and blood draws. By broadly deploying AccuVein devices, Maury Regional ... technology takes much of the guesswork out of a needle stick and more importantly, ...
(Date:8/16/2017)... ... August 16, 2017 , ... LabRoots , the leading provider ... the world, is excited to announce Andrew Ly as the winner of the LabRoots ... textbook costs. , Ly, who is in his third year at the University ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... 15, 2017  AOTI Inc. announced today that its fully owned ... recently opened a New York City Office in Yonkers, ... unique Topical Wound Oxygen (TWO 2 ) homecare therapy. This new ... for Health Care (ACHC) under the company,s DMEPOS accreditation for Home/Durable ... Advanced ...
(Date:8/8/2017)... Second-quarter 2017 revenues of $876 million and ... operations Second-quarter 2017 Branded ... Second-quarter 2017 Sterile Injectables ... Second-quarter 2017 adjusted diluted earnings per ... $0.93 Second-quarter 2017 reported ...
(Date:8/7/2017)... , Aug. 7, 2017  Endo International plc ... reached agreements to resolve virtually all known U.S. mesh ... discussions to resolve the known remaining U.S. claims at ... payments beginning in the fourth quarter of 2017 and ... of its second quarter 2017 results, the Company intends ...
Breaking Medicine Technology: